A more favorable prognosis in patients with HER2+ breast cancer has also been reported [21], and in a large phase III randomized adjuvant breast cancer trial, assessing node-positive, ER− /HER2− BC, Loi S et al., found that high lymphocytic infiltration was associated with excellent prognosis [18]. Here, ERBB2 is linked to breast cancer.